PET After One Chemo Cycle in Hodgkin's Has Predictive Value

A new study indicates that undergoing a PET scan after one cycle of chemotherapy for Hodgkin's is strongly predictive of patients with more favorable outcomes.

Currently the survival rate of most patients with Hodgkin's lymphoma is very high, but this doesn't mean they are exempt from the long-term effects of treatment. This study acknowledged that prior trials have shown that FDG-PET/CT after second and third cycles of chemotherapy is a strong prognostic indicator, and so researchers wanted to see if there was similar prognostic value in doing such a scan following just a single cycle of chemotherapy.

In this prospective, multicenter, observational trial of 126 patients diagnosed with Hodgkin's lymphoma, all patients underwent a PET/CT scan following one cycle of chemotherapy (PET1). Also, 89 patients underwent another scan after the second round of chemotherapy (PET2).

Primary outcomes were progression-free survival, overall survival and end of treatment response.

Researchers concluded that patients with negative findings on PET scans after one round of chemo had significantly increased progression free and overall survival compared to those with positive findings after PET1. They went on to suggest that negative FDG-PET/CT after the first cycle of chemotherapy might aide doctors in selecting patients for less intensive chemotherapy regimens, and therefore spare those patients unnecessary exposure to chemo, and thus lessen the likelihood of them developing long-term effects.

Source: JCO

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap